{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(3)"],"submitter":["Laudani C"],"pubmed_abstract":["<h4>Background and aims</h4>Multiple anti-inflammatory drugs have been tested for secondary prevention after myocardial infarction (MI), giving mixed results and questioning the efficacy of anti-inflammatory therapy. No head-to-head comparisons between anti-inflammatory drugs have been performed. This study aimed to compare the efficacy and safety of anti-inflammatory drugs for secondary prevention after MI and the relative merits of specific drugs and administration strategies.<h4>Methods and results</h4>Randomized trials of anti-inflammatory therapy for secondary prevention after MI were identified. Primary efficacy and safety endpoints were trial-defined major adverse cardiovascular events (MACEs) and serious adverse events. Secondary endpoints included all-cause death, individual MACE "],"journal":["European heart journal. Cardiovascular pharmacotherapy"],"pagination":["218-229"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12046582"],"repository":["biostudies-literature"],"pubmed_title":["A pairwise and network meta-analysis of anti-inflammatory strategies after myocardial infarction: the TITIAN study."],"pmcid":["PMC12046582"],"pubmed_authors":["Laudani C","Capodanno D","Greco A","Giacoppo D","Occhipinti G","Spagnolo M"],"additional_accession":[]},"is_claimable":false,"name":"A pairwise and network meta-analysis of anti-inflammatory strategies after myocardial infarction: the TITIAN study.","description":"<h4>Background and aims</h4>Multiple anti-inflammatory drugs have been tested for secondary prevention after myocardial infarction (MI), giving mixed results and questioning the efficacy of anti-inflammatory therapy. No head-to-head comparisons between anti-inflammatory drugs have been performed. This study aimed to compare the efficacy and safety of anti-inflammatory drugs for secondary prevention after MI and the relative merits of specific drugs and administration strategies.<h4>Methods and results</h4>Randomized trials of anti-inflammatory therapy for secondary prevention after MI were identified. Primary efficacy and safety endpoints were trial-defined major adverse cardiovascular events (MACEs) and serious adverse events. Secondary endpoints included all-cause death, individual MACE ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 May","modification":"2025-06-25T03:06:36.449Z","creation":"2025-06-25T03:06:36.449Z"},"accession":"S-EPMC12046582","cross_references":{"pubmed":["39756386"],"doi":["10.1093/ehjcvp/pvae100"]}}